KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to 42.82%.

  • Gilead Sciences' EBIT Margin rose 310500.0% to 42.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.06%, marking a year-over-year increase of 331600.0%. This contributed to the annual value of 5.78% for FY2024, which is 222700.0% down from last year.
  • Per Gilead Sciences' latest filing, its EBIT Margin stood at 42.82% for Q3 2025, which was up 310500.0% from 34.93% recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' EBIT Margin ranged from a high of 51.77% in Q3 2021 and a low of 64.64% during Q1 2024
  • Over the past 5 years, Gilead Sciences' median EBIT Margin value was 32.41% (recorded in 2022), while the average stood at 25.95%.
  • In the last 5 years, Gilead Sciences' EBIT Margin plummeted by -914800bps in 2024 and then skyrocketed by 982000bps in 2025.
  • Gilead Sciences' EBIT Margin (Quarter) stood at 12.98% in 2021, then skyrocketed by 136bps to 30.68% in 2022, then fell by -26bps to 22.66% in 2023, then soared by 43bps to 32.4% in 2024, then soared by 32bps to 42.82% in 2025.
  • Its EBIT Margin stands at 42.82% for Q3 2025, versus 34.93% for Q2 2025 and 33.55% for Q1 2025.